Table 2.

Study characteristics for general populations without known disease at baseline and incident outcomes

First author, year	Population description	Exposure description(s)	Range of follow-up*	Outcome(s)	Number of studies included in meta-analysis)	Sample size included in meta-analysis	AMSTAR2 rating†
Aune, 202138	General populations of adults	High versus low	6.5–19.1 years	Incidence of heart failure	6	1 505 114	Moderate quality
		Per 1-MET increase			5	173 678
Cheng, 202237	General populations of adults	High versus low	4.3–25.7 years	Incidence of hypertension	9	1 618 067	Moderate quality
		Per 1-MET increase			9	1 618 067
Kandola, 201956	General populations of adults	High versus low	8 weeks to 42 years	Incidence of depression	3	1 145 655	Critically low quality
Kunutsor, 202357	General populations of adults	High versus low	7.2–27.9 years	Incidence of chronic kidney disease	5	32 447	Moderate quality
Lee, 202158	General populations of adults	High versus low	6–38 years	Incidence of dementia	3	11 694	Critically low quality
Pozuelo-Carrascosa, 201940 Data only presented in supplement	General populations of adult men only	High versus low	5–40 years	Incidence of colon/rectum, prostate, skin and all site cancer	4–5	23 350–28 262	Moderate quality
Tarp, 201959	General populations of adults	Per 1-MET increase	3–29 years	Incidence of type 2 diabetes	10	1 601 490	High quality
Wang, 202039	General populations of adults	High versus low	3.9–25.2 years	Incidence of stroke	14	1 409 340	Moderate quality
		Per 1-MET increase			9	Not reported
Xue, 202060	General populations of adults	High versus low	5.0–28.2 years	Incidence of atrial fibrillation	7	2 168 739	Critically low quality
		Per 1-MET increase			7	222 124

*Data presented are for all the papers included in the systematic reviews and may include exposures other than CRF.

†Details on the AMSTAR2 quality assessment are available from Shea et al.³¹

AMSTAR2, A MeaSurement Tool to Assess systematic Reviews 2; CRF, cardiorespiratory fitness; MET, metabolic equivalent of task.